±¹³» ¼ºÀÎȯÀÚ¿¡¼ ÀÌ»óÁöÁúÇ÷Áõ ¾à¹°Ä¡·á¿Í °ñ´Ù°øÁõ »ó°ü¼º
The Association between Medication Use for Dyslipidemia and Osteoporosis
Çѱ¹ÀÓ»ó¾àÇÐȸÁö 2021³â 31±Ç 4È£ p.278 ~ p.284
ÀÌÇѼÖ(Lee Han-Sol) - Dongduk Women¡¯s University College of Pharmacy
±èÁ¾À±(Kim Jong-Yoon) - Dongduk Women¡¯s University College of Pharmacy
À¯±â¿¬(Rhew Ki-Yon) - Dongduk Women¡¯s University College of Pharmacy
Abstract
Background: Osteoporosis is a disease that affects the quality of life and imposes a high socioeconomic burden. Studies have reported that statins, a HMG CoA reductase inhibitor, have a positive or negative effect on osteoporosis. The purpose of this study was to analyze the correlation between statins and osteoporosis risk.
Methods: We used the total patient sample data of the Health Insurance Review and Assessment Service (HIRA-NPS-2018). We analyzed the prevalence of osteoporosis in adult patients of Korea who were diagnosed with dyslipidemia and were prescribed statins at the same time. The odds ratio (OR) according to the intensity and type of statin was used to confirming the prevalence.
Results: Among the 1,138,899 patients included in the study, 143,895 patients used statins and 27,524 patients (19.13%) were diagnosed with osteoporosis in the statin group. The OR value of statin group was 0.96 (95% CI 0.94-0.98), confirming that the prevalence of osteoporosis decreased, and a significant decrease was seen in all statin intensity. Some of the moderate-intensity statins rather increased the prevalence of osteoporosis, but atorvastatin and rosuvastatin obtained positive results at both medium- and high-intensity doses, and lovastatin, a low-intensity statin, showed the greatest reduction in the prevalence of osteoporosis.
Conclusion: We found that the prevalence of osteoporosis was reduced in the statin group, and there was a constant correlation regardless of gender or age. However, a large, prospective, double-blind and randomized study is needed for a long period of time to demonstrate the effectiveness of statins.
Å°¿öµå
Statin, intensity, ezetimibe, dyslipidemia, osteoporosis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
ÀÌ»óÁöÁúÇ÷ÁõÀ» Áø´Ü¹Þ¾Æ ½ºÅ¸Æ¾À» »ç¿ëÇÏ´Â ±¹³» ȯÀÚ¿¡¼ °ñ´Ù°øÁõ À¯º´·üÀÌ °¨¼ÒÇÏ¿´°í(ORadj=0.96; 95% CI 0.94-0.98), ¼ºº°À̳ª ³ªÀÌ¿¡ ¹«°üÇÏ°Ô ÀÏÁ¤ÇÑ »ó°ü¼ºÀ» º¸¿´À½.